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Abstract
Background: Chlamydia trachomatis (chlamydia), the most commonly reported sexually transmitted infection (STI)
in the Netherlands, can lead to severe reproductive complications. Reasons for the sustained chlamydia prevalence
in young individuals, even in countries with chlamydia screening programs, might be the asymptomatic nature of
chlamydia infections, and high reinfection rates after treatment. When individuals are unaware of their infection,
preventive behaviour or health-care seeking behaviour mostly depends on psychological determinants, such as risk
perception. Furthermore, behaviour change after a diagnosis might be vital to reduce reinfection rates. This makes
the incorporation of psychological determinants and behaviour change in mathematical models estimating the
impact of interventions on chlamydia transmission especially important. Therefore, quantitative real-life data to
inform these models is needed.
Methods: A longitudinal cohort study will be conducted to explore the link between psychological and behavioural
determinants and chlamydia (re)infection among heterosexual STI clinic visitors aged 18–24 years. Participants will be
recruited at the STI clinics of the public health services of Amsterdam, Hollands Noorden, Kennemerland, and Twente.
Participants are enrolled for a year, and questionnaires are administrated at four time points: baseline (before an STI
consultation), three-week, six-month and at one-year follow-up. To be able to link psychological and behavioural
determinants to (re)infections, participants will be tested for chlamydia at enrolment and at six-month follow-up. Data
from the longitudinal cohort study will be used to develop mathematical models for curable STI incorporating these
determinants to be able to better estimate the impact of interventions.
Discussion: This study will provide insights into the link between psychological and behavioural determinants,
including short-term and long-term changes after diagnosis, and chlamydia (re)infections. Our mathematical model,
informed by data from the longitudinal cohort study, will be able to estimate the impact of interventions on chlamydia
prevalence, and identify and prioritise successful interventions for the future. These interventions could be
implemented at STI clinics tailored to psychological and behavioural characteristics of individuals.
Trial registration: Dutch Trial Register NTR-6307. Retrospectively registered 11-nov-2016.
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Background
Chlamydia trachomatis (chlamydia) is the most com-
monly diagnosed bacterial STI among young heterosex-
ual men and women in many western countries,
including the Netherlands with up to 55,000 diagnosed
infections in STI clinics nationally each year [1]. Control
of this infection is of public health importance, because
it can cause severe reproductive complications, including
pelvic inflammatory disease (PID), ectopic pregnancy
and tubal subfertility [2–5]. However, it is unclear why
the prevalence of chlamydia remains unchanged even in
countries with chlamydia screening programs, such as
England, Australia, Canada, and the United States [6].
A difficulty in controlling chlamydia transmission is
that most infections are asymptomatic [7]. Since people
are unaware of their infection, initiation of preventive
behaviours (i.e., condom use), or health-care seeking be-
haviour (i.e., chlamydia testing), mostly depends on
psychological determinants, such as risk perception,
self-efficacy or attitudes regarding condom use [8–11].
Previous studies have mainly focussed on identifying be-
havioural risk factors for chlamydia infection [12–15],
while understanding how psychological determinants in-
fluences such behaviour might be more informative for
the development of effective interventions [10]. For ex-
ample, an increased number of sexual partners has pre-
viously been identified as a risk factor for chlamydia
infection [12, 14], but having many sexual partners
might not necessarily be risky if people would realistic-
ally perceive their risk for acquiring a STI and take the
necessary steps to protect themselves. Therefore, study-
ing the link between psychological determinants and be-
haviour and relating these to chlamydia infections might
increase our understanding of chlamydia transmission.
For instance, many young people tend to underestimate
their personal risk of acquiring chlamydia [8, 16], which
could have a negative effect on their condom use and
testing uptake [8, 10, 17].
Another reason for the sustained chlamydia prevalence
might be high reinfection rates after treatment or natural
clearance [15, 18–20].To reduce the risk of reinfections,
behaviour change (i.e., more consistent condom use)
might be essential [21, 22]. Several studies have shown
that individuals who were diagnosed with an STI were
more likely to change into less risky sexual behaviour
after they received the test results than individuals who
tested negative [21, 23–27], but the influence of STI test
results on underlying psychological determinants are not
known. Behaviour change might be dependent on a
number of psychological determinants, such as risk per-
ception, perceived norms, perceived susceptibility,
self-efficacy, knowledge, intentions, and attitudes regard-
ing condom use [8–11, 17]. For example, while increased
perceived risk of STI as a result of a positive diagnosis
might induce behaviour change, receiving negative test
results could lead to a false sense of security in high-risk
individuals, and changing their risky sexual behaviour
after the STI test may be deemed unnecessary [24].
However, regardless of the diagnosis, fear experienced
before receiving the STI test results [17], might provide
enough motivation to increase condom use. Quantitative
longitudinal data is needed to explore the interplay be-
tween psychological and behavioural determinants after
diagnosis and over time.
Longitudinal data on psychological and behavioural
determinants could be used to investigate the impact of
interventions aimed at reducing chlamydia (re)infections
in mathematical models. Mathematical models are a tool
for understanding the transmission of infectious diseases
and establish a scientific basis for decision-making [28].
Predictions of the impact of interventions on prevalence
arising from these models can be used to inform na-
tional health policies [29, 30]. However, psychological
determinants are hardly ever incorporated in mathemat-
ical models describing STI transmission, and many
models do not take into account that behaviour can
change over time. Incorporating psychological determi-
nants and behavioural change might improve the estima-
tion of the impact of interventions on chlamydia
prevalence in mathematical models. It may also increase
our understanding on how to control chlamydia trans-
mission more effectively, for example by identifying core
risk groups that contribute most to transmission.
To explore the link between (changes in) psychological
and behavioural determinants, and chlamydia (re)infec-
tion, a study called ‘Mathematical models incorporating
Psychological determinants: control of Chlamydia Trans-
mission’ (iMPaCT) was initiated. A longitudinal cohort
study will be conducted among individuals testing for
chlamydia at the STI clinic. Individual data on (re)infec-
tion rates, psychological determinants, and behaviour
will be collected at different points in time to link these
to chlamydia (re)infections and to study changes over
time. These changes include short-term changes after a
diagnosis, and long-term changes (1 year after a diagno-
sis at baseline). Mathematical models will be developed
incorporating psychological and behavioural determi-
nants using data from the longitudinal study. We will
explore how incorporating these variables, including
short- and long-term changes, influence chlamydia
prevalence estimations from models.
Methods
Study aim
The aim of the iMPaCT study is to explore the link be-
tween psychological and behavioural determinants, and
chlamydia (re)infection among heterosexuals aged
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18-24 years visiting STI clinics. The following aims will
be addressed:
1. To identify predictors of chlamydia infection;
– What demographic, psychological, and behavioural
determinants are associated with chlamydia infection?
2. To investigate short-term and long-term changes
(or stability) in psychological determinants and
sexual behaviour over time;
– What is the influence of a chlamydia test result
(positive or negative) on psychological determinants
and subsequent sexual behaviour?
– Regarding these determinants, does change (or
stability) in psychological and/or behavioural
determinants affect the probability of reinfection?
– How do psychological and behavioural determinants
change over time during 1 year of follow-up?
3. To explore the influence of psychological
determinants on the predicted impact of
intervention measures to reduce chlamydia
transmission by mathematical models;
4. To explore the influence of changes in psychological
determinants and sexual behaviour on the predicted
impact of intervention measures to reduce chlamydia
transmission by mathematical models.
Design
A longitudinal cohort study will be conducted among
young heterosexual STI clinic visitors in the
Netherlands.
Setting
Participants will be recruited from STI clinics of the
Public Health Services (GGD) of Amsterdam, Kenne-
merland, Hollands Noorden, and Twente. In 2015, these
STI clinics tested around 20,000 heterosexual men and
women under the age of 25 for chlamydia according to
the national registry. The majority of this group was fe-
male, ≥ 20 years old, and Dutch, and approximately 15%
tested positive for chlamydia [31].
Study population
Heterosexual men and women aged 18 to 24 years visit-
ing the STI clinic of the GGD Amsterdam, Kennemer-
land, Hollands Noorden, or Twente are eligible to
participate. All enrolled individuals will be invited for
follow-up data collection moments, irrespective of their
test result at baseline. Individuals, who are not living in
the Netherlands, are not able to read or speak Dutch,
commercial sex workers, men who have sex with men
(including men who have sex with both men and
women), and women who have sex with women, will be
excluded from participation in this study. Women who
have sex with both men and women will only be ex-
cluded if their last three partners were women.
Recruitment
Participants will be recruited during the process of making
an appointment at the STI clinic. To fit the study into the
daily flow of the STI clinics, two different procedures will
be applied. At the GGD Amsterdam, Kennemerland, and
Hollands Noorden, individuals who are eligible to partici-
pate will be invited during the process of making an ap-
pointment online. Individuals will receive information
about iMPaCT when they confirm their appointment. At
the GGD Twente, the receptionist will invite individuals
who are eligible to participate when they are making an
appointment by telephone, and send them an email with
information about iMPaCT. Recruitment is expected to
take approximately 6 to 8 months.
Inclusion and follow-up
Participants will be enrolled for 1 year, and data on (re)-
infection rates, psychological determinants, and behav-
iour will be collected at four different points in time to
link these to chlamydia (re)infections and study changes
(or stability) in psychological determinants and sexual
behaviour over time. Data collection will occur at the
following time points: at baseline, three-week follow-up,
six-month follow-up and at one-year follow-up (Fig. 1).
At baseline, individuals eligible to participate will be
invited during the process of making an appointment at
the STI clinic. If an individual agrees to participate, an
online questionnaire (the questionnaire is described in
more detail below) will be administered, which starts
after participants gave informed consent. Subsequently,
participants are tested for chlamydia at the STI clinic.
During the consultation at the STI clinic, the partici-
pants will receive information on prevention of STI and
motivational-interviewing based counselling from the
nurses. Since this might have an effect on psychological
and behavioural determinants [32] and possibly lead to
biased answers, participants will complete the baseline
questionnaire before the consultation. Therefore, partici-
pants have approximately 1 to 2 weeks to fill out the
questionnaire, between making their appointment and
their STI clinic visit. Individuals who agree to participate
will receive an email, as a reminder, with information
about iMPaCT and a web link, which will guide them
directly to the online questionnaire. Participants, who
completed the questionnaire after their consultation at
the STI clinic, will be excluded.
The participants will receive the chlamydia test results
within 2 weeks of the STI clinic visit. Approximately 1
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week after the communication of the test results (three
to 4 weeks after the STI clinic visit), all participants who
completed the baseline questionnaire will be invited via
email to fill out the second questionnaire online. Partici-
pants, who have not finished the second questionnaire,
will receive two reminders by email: 1 week and 2 weeks
after the invitation for the second questionnaire.
The third data collection moment will take place 6
months after baseline, because reinfections usually occur
within 6 months after the initial infection [15, 18, 33,
34]. Firstly, all participants who completed the baseline
questionnaire will be invited via email to fill out an on-
line questionnaire. Additionally, all participants will be
invited for a retest, irrespective of the test result at base-
line. They will receive a self-swab test-kit at their home
address or another preferred address, as specified in the
third questionnaire, in a plain package fitting letterboxes.
In this package, the participants will find simple instruc-
tions about the type of sample that they need to provide
(urogenital test only, urine sample for men and vaginal
swab for women) and how to collect these samples. Sub-
sequently, the participants mail the testing-kits directly
to the laboratory for chlamydia and gonorrhoea testing.
The results will be communicated within three working
days after the arrival of their material in the laboratory,
via email with a link to a secured webpage, where the
participants can download the results of their test with
the login data attached in the email. Participants, who
have not finished the online questionnaire, will receive
two reminders by email: 1 week and 2 weeks after the
invitation for the third questionnaire. Participants, who
have completed the online questionnaire, but who have
not mailed the test-kit to the laboratory, will receive two
reminders by email: 2 weeks and 4 weeks after the
test-kits are sent. The number of reminders for the re-
test will be the same as the number of reminders for the
questionnaires, but the reminders will be spread further
apart due to the possibility of delays in the logistics of
the retest. Participants, who test positive, will be advised
to make an appointment with their GP or at the STI
clinic for appropriate treatment. A letter for the GP or
STI clinic with information about the iMPaCT study,
and a copy of the laboratory results will be provided.
Finally, 1 year after baseline, all participants who com-
pleted the baseline questionnaire will be invited via
email to fill out the fourth online questionnaire. Partici-
pants, who have not finished the online questionnaire,
will receive two reminders by email: 1 week and 2 weeks
after the invitation for the fourth questionnaire. After
completing the last questionnaire, irrespective of com-
pleting the three-week and six-month follow-up ques-
tionnaires, participants will receive a gift voucher with a
value of €5 within a week (by mail).
Demographic and consultation information
National STI surveillance data will be used to comple-
ment the information gathered in the questionnaires.
This surveillance data includes routinely registered data
of all consultations from all STI clinics in the
Netherlands, such as demographic information (i.e. age,
sex, ethnicity and level of education), previous testing
behaviour, previous STI diagnosis, reason for testing
(i.e., notified by chlamydia-positive partner, symptoms),
several behavioural determinants and STI test results. In
the surveillance data, each STI clinic visitor has an an-
onymous identification (ID) number. This ID number
November 2016 – June 2017: 
Inclusion period
December 2016 – July 2017:
Three-week follow-up
May 2017 – December 2017:
Six-month follow-up
November 2017 – June 2018:
One-year follow-up
Baseline questionnaire
CT test: STI clinic
Second questionnaire
Third questionnaire
CT test: home-based sampling kit
Fourth questionnaire
Fig. 1 Flowchart of the longitudinal cohort study. CT = Chlamydia trachomatis
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will automatically be incorporated in the web link to the
questionnaire, which enables linkage of the surveillance
data to the questionnaire. To identify chlamydia reinfec-
tions before the retest at six-month follow-up, informa-
tion on STI clinic visits between baseline and six-month
follow-up of the participants will also be extracted from
the national STI surveillance data using this ID number,
including the reason for their visit and the test result.
Laboratory testing
The chlamydia-test performed at baseline is routine prac-
tice of the consultation at the STI clinic, using nucleic acid
amplification tests (NAAT) to detect chlamydia, such as
Transcription-mediated amplification (TMA) or polymer-
ase chain reaction (PCR). Six months after baseline, all
participants will be invited for a retest, irrespective of the
test result at baseline. Home-based sampling and return-
ing test kits to a laboratory by mail can be used to test for
STI, such as chlamydia and gonorrhoea [18, 35–39]. The
testing-kits can be mailed directly to the laboratory using
the pre-paid return envelope provided. All samples will be
tested for chlamydia and gonorrhoea using NAAT/PCR,
with respectively a sensitivity of 97.0 and 99.3% and speci-
ficity of 98.9 and 99.3% [38].
Defining chlamydia (re)infection
Chlamydia infection at baseline will be defined as
confirmed positive NAAT-results for Chlamydia tracho-
matis at any anatomic location (urogenital, anorectal,
pharyngeal) at the STI clinic. Chlamydia reinfection will
be defined as confirmed positive NAAT-result for Chla-
mydia trachomatis based on either the samples provided
by the participants at six-month follow-up through the
self-swab testing kit (urogenital only) and/or a test at the
STI clinic between baseline and six-month follow-up at
any anatomic location (urogenital, anorectal, pharyngeal).
Questionnaires
We have conducted a pilot survey in May 2016 among
296 heterosexuals aged 16–34 to evaluate the concise-
ness and the comprehensibility of the online question-
naire using factor and reliability analysis and comments
from the respondents. People were recruited via social
media and at a vocational school in Amersfoort, the
Netherlands. The duration of the questionnaires in the
iMPaCT study was estimated based on the results from
this pilot survey; the questionnaire at baseline will take
about 10–15 min and the other questionnaires will take
less than 10 min. All questionnaires will be sent via For-
mdesk [40], a tool to create and manage online forms.
Each participant has an anonymous study ID number,
which will be used to link the questionnaire data from
Formdesk to the information in the national STI surveil-
lance data.
The baseline questionnaire has two parts: one part on
psychological determinants, and one part on sexual behav-
iour. Psychological determinants included in the question-
naires that might play a role in acquiring STI are; risk
perception [41–45], impulsiveness [46–50], intentions re-
garding condom use [11, 51], attitudes regarding preven-
tion of chlamydia [52, 53], health goals [9, 51], knowledge
[11], stigma [54–56], shame [54–56], anxiety [54–56],
self-efficacy [43, 57], social support [11], peer norms [11]
and self-esteem [58]. These determinants were included in
the questionnaire based on associations in the literature
with sexual risk behaviour, testing-behaviour, and behav-
ioural change. Answers to these questions are measured
on a 5-point Likert scale.
The questions about sexual behaviour are based on sev-
eral validated questionnaires, including questionnaires
from previous STI studies [11, 59–61], and the UK NAT-
SAL [13]. Participants will be asked about the number of
sex partners, age at sexual debut, condom use, and we will
pose detailed questions on the last three partners, includ-
ing begin and end of the partnership, condom use, sex fre-
quency, type of sex, and partner characteristics.
The follow-up questionnaires will be the same as the
baseline questionnaire, with a few additional questions.
To explore short-term effects of diagnoses (and if applic-
able treatment) on possible changes in psychological and
sexual behaviour determinants, the questionnaire at
three-week follow-up will include the same questions on
psychological determinants and sexual behaviour as the
baseline questionnaire. For participants who test positive
at baseline, questions are added about partner notifica-
tion in the week following treatment. In the question-
naire at six-month and one-year follow-up, questions
will be added about visits to the STI clinic between base-
line and six-month follow-up and between six-month
follow-up and one-year follow-up, including test results,
treatment, and reasons for the visit(s).
Expected response
Based on the number of consultations at the STI clinics
of the public health services in Twente, Hollands Noor-
den, Kennemerland and Amsterdam in the last 6 months
of 2015 in the national registry, around 10,000 hetero-
sexual STI clinic visitors will meet the inclusion criteria
during 6 months of recruitment (40% men and 60%
women). Table 1 shows the expected response for each
data collection moment by STI clinic. The response rate
at baseline is expected to be low, because recruitment at
baseline is internet-mediated (passive recruitment) and
there will be no face-to-face interaction with potential
participants [62, 63]. We aim to include 2000 people at
baseline (20% response rate), of which 800 are men and
1200 are women, based on the distribution of heterosex-
ual male and female visitors at the STI clinics [31]. We
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expect 15% of the participants at baseline to test positive
(N = 300) [31].
The response rates at the follow-up moments are ex-
pected to be higher than at baseline, because the partici-
pants will receive personal invitations by email instead
of the impersonal baseline invitation addressed to all the
STI clinic visitors who were eligible to participate. How-
ever, the response rates might decline over time [30]. At
three-week follow-up, a response rate of 80% (N = 1600)
is expected (this includes sending reminders) [30]. All
participants will be contacted by email again at the
six-month follow-up, also participants who did not re-
spond to the three-week follow-up. The participation
rate at six-month follow-up among people who tested
chlamydia positive at baseline is expected to be around
66% [18], and the participation rate is likely to be lower
for individuals who tested chlamydia negative at baseline
[24] and is expected to be around 45%. Therefore, ap-
proximately 1000 participants will be tested for chla-
mydia at six-month follow-up. We expect 15% of the
participants that were chlamydia negative (Ct-) at base-
line and 20% of the participants that were chlamydia
positive (Ct+) at baseline to test positive at six-month
follow-up (N = 155) [31, 33, 34]. All participants who
completed the baseline questionnaire will be contacted
again at the one-year follow-up, also participants who
did not respond to the three-week follow-up and/or the
six-month follow-up, and we expect a response rate of
30% (N = 600). Participants can choose to leave the study
at any time for any reason. If participants formally with-
draw from the study by email, they will not be invited
for follow-up data collection.
Sample size and power calculations
To explore if the study population will be large enough to
detect differences in psychological and behavioural deter-
minants between baseline and six-month follow-up with
adequate statistical power, sample size and statistical
power calculations were performed in Stata version 13.0
[64]. Firstly, sample size calculations for at least 80%
power were performed for the participants who tested
positive (Ct+) and participants who tested negative for
chlamydia at baseline (Ct-), assuming a type I error (α) of
0.05, 34% loss to follow-up after 6 months in the Ct +
group, and 55% loss to follow-up after 6 months in the
Ct- group (based on the expected response rates described
above). Secondly, power calculations were performed with
the expected sample size of 2000 participants at baseline,
assuming 15% chlamydia positivity (n = 300) [31].
The sample size and power calculations for sexual be-
haviour were calculated with condom use as an example.
Soetens et al., (2015) [26] found that condom use 1 year
after the chlamydia test at baseline increased in the Ct +
group and decreased in the Ct- group. Based on these re-
sults, the percentage of participants in our study using a
condom with the last sexual contact was assumed to in-
crease in individuals after a Ct + baseline test and decrease
in individuals after a Ct- baseline test. The sample size
and power for sexual behaviour were calculated for three
different scenarios: 10 (scenario 1), 15 (scenario 2), or 20
(scenario 3) percent change at six-months follow-up
(Table 2).
This is, to our knowledge, the first study assessing
changes in psychological determinants after diagnosis of
chlamydia or over a longer period of time. Therefore, no
literature is available to inform possible changes in psy-
chological determinants in our sample size calculations.
The sample size and power calculations for the psycho-
logical determinants were calculated with risk perception
as an example, but this can also be generalised to other
psychological determinants. Research has shown that
people chronically underestimate their personal risk of
acquiring chlamydia [8]. Tailored risk information (i.e.
after a consultation at the STI clinic) might increase an
individual’s perceived risk for STI [65]. Furthermore, in-
dividuals with previous STI diagnoses are more likely to
report higher perceived risk for STI than those with no
previous STI diagnoses [66, 67]. Therefore, we hypothe-
sized that risk perception, which will be assessed in the
questionnaire as the estimated personal risk of chla-
mydia on a scale from 0 to 100, might increase in indi-
viduals after a Ct + baseline test and decrease in
individuals after a Ct- baseline test. The sample size and
power for the psychological determinants were calcu-
lated with the same hypothesized percent change as for
sexual behaviour (Table 2).
Table 1 Expected number of participants per STI clinic at each follow-up moment
STI clinic Expected number of participants
Baseline (men/women) Baseline Ct+ Three-week Six-month Six-month Ct+ One-year
Twente 400 (160/240) 60 320 193 31 120
Hollands Noorden 400 (160/240) 60 320 193 31 120
Kennemerland 400 (160/240) 60 320 193 31 120
Amsterdam 800 (320/480) 120 640 385 62 240
Total 2000 (800/1200) 300 1600 964 155 600
Abbreviations: Ct+ chlamydia positive
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The expected sample size of 2000 participants will be
large enough to detect a change of 10–20% in psychological
determinants and behavioural with adequate statistical
power (power > 80%). The expected sample size of 300 in
the Ct + group is too small for detecting 10% change
(scenario 1) for ≥70% power, but the expected sample size
is sufficient for detecting ≥15% change (scenario 2 and 3),
which might be more likely in this group [26].
Statistical analyses
The main analysis will include all participants who com-
pleted the baseline questionnaire, irrespective of their
test result. Possible response bias will be explored in a
(non-)response study using anonymised national STI sur-
veillance data of all individuals eligible to participate who
visited the STI clinic in the inclusion period. Demographic
characteristics, sexual behaviour, and STI consultation in-
formation will be compared between participants who
completed the baseline questionnaire, and all the STI
clinic visitors who were invited to participate, but did not
complete or start the baseline questionnaire. The partici-
pants who completed the baseline questionnaire will be
identified in the surveillance data, using the previously de-
scribed ID number incorporated in the web link to the
questionnaire.
We expect only few missing values in the completed
baseline questionnaires, because each question has to be
answered before the next question appears. Furthermore,
data consistency checks will be incorporated in the online
questionnaire. Missing values in variables extracted from
the national STI surveillance data or in the second, third
and last questionnaire due to loss to follow-up will be in-
cluded as a separate category if more than 5% is missing.
Baseline characteristics of the study population will be
presented, using summary statistics, including means,
standard deviations, medians and ranges for continuous
variables and frequency distributions for binary and cat-
egorical variables. To identify predictors of participation
in the (non-)response study, and to identify predictors of
chlamydia (re)infection, univariable and multivariable lo-
gistic regression analysis will be performed. In the uni-
variable analysis, variables significantly associated with
the outcome (participation or chlamydia (re)infection)
will be included in the multivariable models.
Multivariable models will be constructed using a back-
ward elimination procedure. Statistical significance will
be defined as a p-value ≤0.1, and odds ratios and 95%
confidence intervals of each predictor variable will be re-
ported. Covariates based on a priori hypotheses will be
examined as potential confounder or effect modifiers in
the models.
To identify distinct risk groups for chlamydia (re)infec-
tion, based on the results of the multivariable logistic re-
gression analysis, we will use latent class analysis for
multivariable categorical data. In this analysis, under-
lying dimensions (latent classes) of the dependent vari-
ables can be inferred based on patterns in the observed
data. The latent classes arising from this analysis could
be combinations of several measured psychological, be-
havioural and demographic variables. Covariates that are
independent of the outcome, but might influence the la-
tent classes will be included in the analysis. The number
of latent classes will be determined by increasing the
number of classes until the best fitting model has been
found, using the Bayesian Information Criterion (BIC) to
assess the goodness of fit. The latent classes can be used
to define distinct sexual risk profiles, which can be im-
plemented in future mathematical models.
To explore changes in psychological determinants and
sexual behaviour over time using data from the
three-week, six-month, and one-year follow-up moments,
and to identify risk profiles for chlamydia reinfection, we
will use latent transition analysis, which is an extension of
the latent class analysis described above. In this analysis,
movement from one latent class to another over time can
be determined. Similar to the latent class model, the BIC
will be used to assess how well the latent transition model
fits the observed data. The estimated transition probabil-
ities can be implemented in future mathematical models
of the transmission of chlamydia, which might enable us
to better capture the complexity of sexual behaviour.
Mathematical model
The mathematical model will be a pair compartmental
model representing a heterosexual population of men
and women aged 18–24 years. Chlamydia will be de-
scribed with a susceptible-infected-susceptible (SIS)
structure. The infection parameters for chlamydia are
Table 2 Sample size and power calculations for different scenarios
Change (%) Sample size needed at baseline (80% power) Expected power with sample size n = 2000 at baseline
Ct+ Ct- Ct + (n = 300) Ct- (n = 1700)
Scenario 1 10% 470 611 60% > 99%
Scenario 2 15% 220 286 91% > 99%
Scenario 3 20% 129 167 > 99% > 99%
Sample size and power calculations to detect a change in psychological determinants or sexual behaviour at six-month follow-up with at least 80% power,
assuming 34% loss to follow-up in the chlamydia positives (Ct+) and 55% loss to follow-up in the chlamydia negatives (Ct-)
Abbreviations: Ct+ chlamydia positive, Ct- chlamydia negative
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reasonably well established and will be used from the
available literature. The transmission rate per sex act will
be calibrated to the positivity rate found at baseline. The
model population will be subdivided into risk groups ac-
cording to the risk classes identified in the latent class
model (based on psychological and behavioural determi-
nants from the baseline questionnaire).
Behavioural change after a diagnosis and in time will
be incorporated by moving people from one risk group
to another based on the latent transition model. First,
we will explore the influence of a diagnosis on
short-term changes of psychological and behavioural de-
terminants in the model. This data will be based on dif-
ferences between the baseline, three-week, and the
six-month follow-up questionnaires. Second, we will the-
oretically explore the effect of long-term behaviour
change on the impact of intervention measures, using
the questionnaire data at one-year follow-up.
Discussion
The iMPaCT study will provide insights into the link be-
tween psychological determinants and sexual behaviour,
behavioural change, and chlamydia (re)infections. We
propose that incorporating these determinants in math-
ematical models will improve the impact assessment of in-
terventions aimed at reducing chlamydia transmission.
Chlamydia interventions that have been applied in prac-
tice have mainly focused on increasing testing uptake, and
previous mathematical modelling studies have shown that,
depending on the coverage of chlamydia testing in the
general population, testing and treatment could be an ef-
fective strategy to reduce chlamydia prevalence, [30, 68,
69]. However, empirical studies have established that the
coverage of chlamydia testing has not been high enough
to observe a significant reduction in the population preva-
lence of chlamydia [13, 61, 70]. Therefore, a paradigm
shift is needed to control chlamydia transmission more ef-
fectively. For example, interventions could be focused on
increasing testing uptake among core risk groups based
on psychological and behavioural characteristics to pre-
vent reinfection after a diagnosis. Our mathematical
model informed by the data of the cohort study will be
able to estimate the impact of such interventions on chla-
mydia prevalence, and identify and prioritise successful in-
terventions for specific risk groups, which might lead to
more efficient ways to control chlamydia transmission.
Subsequently, these interventions could be implemented
at STI clinics tailored to psychological and behavioural
characteristics of individuals.
Strengths
This is the first longitudinal cohort study investigating
short-term and long-term changes in psychological deter-
minants and sexual behaviour after chlamydia diagnosis.
The prospective study design of this study with repeated
measurements, namely the follow-up questionnaires and
the retest, and the combination of an extensive selection
of psychological determinants will expand our knowledge
of risk factors for (re)infection. Another strength of this
study is the combination of two data sources: longitudinal
questionnaire data on psychological determinants and sex-
ual behaviour, and national STI surveillance data on
demographics, previous testing behaviour, and laboratory
confirmed STI diagnosis. Therefore, we are able to obtain
extensive knowledge with a relatively concise question-
naire, because questions on demographics, previous test-
ing behaviour, STI diagnosis and other variables that are
available in the national STI surveillance could be omitted
in the online questionnaire.
The pilot survey, which has been conducted a few
months before the start of iMPaCT study, enabled us to
improve the comprehensibility of the questionnaire.
This, in combination with sending reminder emails and
offering incentives (gift voucher, free home-based sam-
pling kit), might lead to higher response and completion
rates [71]. Furthermore, the psychometric evaluation of
the pilot survey and the advantages of using online ques-
tionnaires, such as programmed warning alerts to pre-
vent incorrect answers (i.e., number of partners last 6
months can’t be higher than the number of partners in
the last year), ensured optimal reliability and validity of
the longitudinal questionnaire data.
Finally, most mathematical models for infectious disease
transmission incorporating behaviour change are entirely
theoretical and lack validation with empirical data [72].
Our mathematical model will be informed by real-life data
on behaviour change, which might result in more realistic
model estimations and the opportunity to validate the
model outcomes. The model outcomes could be directly
translated into to advice for public health policy makers
about effective intervention measures.
Limitations
First, the questionnaire data is self-reported, which could
lead to reporting bias, such as under- or over-reporting
of sexual behaviour. Although sexual behaviour in the
national STI surveillance data is also self-reported, and
thus prone to bias, sexual behaviour in the surveillance
data will be matched to sexual behaviour as reported in
the questionnaire to check for consistency. Furthermore,
being notified for an STI or having STI-related symp-
toms might affect answers in the questionnaire [54, 67]
and this will be taken into account in the statistical ana-
lyses. Response bias may also occur, and we will assess
this in a (non-)response study by extracting the iMPaCT
participants from the national STI surveillance data, and
compare demographics, sexual behaviour, and STI con-
sultation information between the participants and all
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eligible STI clinic visitors who were invited to participate,
but did not complete or start the baseline questionnaire.
We will use this (non-)response study to estimate the
generalizability of the iMPaCT study population with ref-
erence to all young heterosexual STI clinic visitors and to
guide the interpretation of the results. The iMPaCT study
population is not likely to be representative of the general
population, as STI clinic visitors tend to be more high-risk
compared to the general population. However, this group
potentially benefits the most from improved interventions.
Thus, in this study we will gather detailed information for
exactly the group of interest.
Previous longitudinal chlamydia studies have shown
that response rates decline over time and our study will
most likely not be an exception [18, 30]. To minimize
loss to follow-up, free home-based sampling kits and
promised monetary incentives will be used to encourage
participation rates at six-month and one-year follow-up.
The samples size and power calculations, taking loss to
follow-up into account, showed that through recruit-
ment at multiple STI clinics in different regions of the
Netherlands, a sufficiently large and nationally represen-
tative group of STI clinic visitors can be approached for
participation in the iMPaCT study.
It is likely that periods of high and low risk behaviour
alternate during individual sexual careers [73], such as a
period of high risk sexual behaviour after separating
from a long standing partnership. Therefore, the timing
of the follow-up data collection moments is crucial. For
example, it could be argued that the period between the
follow-up questionnaire after 3 weeks and baseline is too
short to detect changes in sexual behaviour, and the
questionnaires 6 months and 1 year after baseline might
not be long-term enough to capture changes in people’s
behaviour that are not necessarily offset by an event
such as a diagnosis. However, we speculate that the ef-
fect of a positive STI diagnosis on psychological deter-
minants, such as intentions and attitudes regarding
condom use, might be strongest in the first few days
after receiving the test results. Furthermore, the optimal
timing of testing for reinfections is not known, and the
recommended timing of retesting across different coun-
tries ranges between 3 to 12 months [74, 75]. Therefore,
participants will be invited for the retest 6 months after
the baseline chlamydia test combined with a question-
naire, and after the same length of time (6 months after
the retest), the participants will be invited to fill out the
last questionnaire at one-year follow up.
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